1Genmab to Submit Biologics License Application to U. In June 2022, primary results were presented in a late-breaking oral presentation as part of the Presidential Symposium at the 27th Annual Meeting of the European Hematology Association (EHA2022) in Vienna, Austria. In April 2022, Genmab and AbbVie announced the topline results from EPCORE NHL-1 trial.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
❌ Licensing Agreement: Not reported
❌ Regulatory Milestone: Not reported
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: :Marisol Peron, Senior Vice President, Communications and Corporate AffairsT: +1
🌍 Genmab (GMAB) - Form 6-K Filing
Filing Date: 2022-06-30
Accepted: 2022-06-30 14:32:16
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: